Evotec SE (ETR:EVT)
Germany · Delayed Price · Currency is EUR 4.305
-0.070 (-1.60%)
At close: Mar 27, 2026
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue
796.97M
Revenue Growth
+467.20%
P/S Ratio
1.01
Revenue / Employee
157.96K
Employees
4,788
Market Cap
763.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 250.52M | 50.01% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 334.83M | 825.21% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.58B |
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.87B |
| Merck KGaA | 21.10B |
| Redcare Pharmacy NV | 2.94B |
| Gerresheimer AG | 2.25B |
| Medios AG | 2.08B |
| RHÖN-KLINIKUM Aktiengesellschaft | 1.97B |
Evotec SE News
- 2 days ago - EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 2 days ago - EQS-AFR: Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 6 days ago - Evotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - Finanz Nachrichten
- 6 days ago - Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - Accesswire
- 10 days ago - Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Accesswire
- 18 days ago - Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 19 days ago - Evotec SE Analyst Call Transcript - GuruFocus
- 19 days ago - Evotec Restructuring Aims To Improve Profitability After Transition Year - Benzinga